MCL1 and posterior cortical atrophy: Taken together, these data demonstrate that MCL1 is highly expressed in CRPC, associates with worse clinical outcome, and may be regulated by pathways implicated in therapy resistance, suggesting MCL1 may be an important therapeutic target in lethal PCa.